The Role of Neurotrophins in Multiple Sclerosis—Pathological and Clinical Implications
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease of the central nervous system (CNS) with unknown etiology. It was recently suggested that autoimmunity, which had long been considered to be destructive in MS, might also play a protective role in the CNS of MS patients. Neurotrophins are polypeptides belonging to the neurotrophic factor family. While neurotrophins mediate cell survival and proliferation in the nervous system, they are also expressed within peripheral blood mononuclear cells fraction (PBMCs) of immunological system. In MS additional neurotrophic support from PBMCs might compensate relative neurotrophins deficiency in the damaged CNS tissue that needs to be repaired. Failure to produce the adequate neurotrophins concentrations might result in decreased protection of the CNS, consequently leading to increased atrophy, which is the main determinant of MS patients’ end-point disability. There are several lines of evidence, both from clinical research and animal models, suggesting that neurotrophins play a pivotal role in neuroprotective and neuroregenerative processes that are often defective in the course of MS. It seems that neuroprotective strategies might be used as potentially valuable add-on therapies, alongside traditional immunomodulatory treatment in multiple sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298 · cited 2×
“In MS PBMC-derived neurotrophins could play a neuroprotective role directly, binding to trk receptors on neurons within the CNS and promoting their survival, or indirectly by interacting with the neurotrophin receptors on the immune cells, regulating their functions (proliferation, immunoglobulin production) and deter…”
Neurotrophin-regulated signalling pathways
Reichardt, L. F. (2006) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2006.1894 · Cited by 2,195
Neurotrophin signal transduction in the nervous system
Kaplan, D. R., & Miller, F. D. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00092-1 · Cited by 1,944 · cited 2×
“pathways as Ras/ERK and Akt/PI3K, both promoting cell survival [11,13].”
Regulation of Cell Survival by Secreted Proneurotrophins
Lee, R., Kermani, P., Teng, K. K., & Hempstead, B. L. (2001) · Science · doi:10.1126/science.1065057 · Cited by 1,670
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050 · cited 1×
“Indeed, several attempts have been made to use neurotrophin-related pathways in therapy for other CNS disorders with a degenerative component, in which decreased neurotrophic activity was described, namely AD, Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington’s disease [63–67].”
TNF receptor 2 pathway: drug target for autoimmune diseases
Faustman, D., & Davis, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3030 · Cited by 446 · cited 1×
“and more limited TNFR-2 [18].”
Cited by
Progressive multiple sclerosis: from pathogenic mechanisms to treatment
Correale, J., Gaitán, M. I., Ysrraelit, M. C., & Fiol, M. P. (2016) · Brain · doi:10.1093/brain/aww258 · Cited by 573
Gómez-Virgilio, L., Silva-Lucero, M.-D.-C., Flores-Morelos, D.-S., Gallardo-Nieto, J., Lopez-Toledo, G., Abarca-Fernandez, A.-M., Zacapala-Gómez, A.-E., Luna-Muñoz, J., Montiel-Sosa, F., Soto-Rojas, L. O., et al. (2022) · Cells · doi:10.3390/cells11152262 · Cited by 431
de Klein, N., Tsai, E. A., Vochteloo, M., Baird, D., Huang, Y., Chen, C.-Y., van Dam, S., Oelen, R., Deelen, P., Bakker, O. B., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01300-6 · Cited by 272
Nuzziello, N., Vilardo, L., Pelucchi, P., Consiglio, A., Liuni, S., Trojano, M., & Liguori, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113652 · Cited by 46
“The most significant was the neurotrophin signalling pathway that recruited four DE miRNAs (miR-125a-5p, miR-320a, miR-185-5p, and miR-25-3p), 18 miRNA targets, and six TFs (RELA, TP53, NF-κB1, FOXO3, JUN, ABL1), thus confirming the pivotal role of neurotrophin in neuroprotective and neurodegeneration processes of MS…”
Background
Metadata
- Authors
- Kalinowska-Lyszczarz, A., & Losy, J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2012-10-22
- Volume
- 13
- Issue
- 10
- Pages
- 13713-13725
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2035146882
- Cited by
- 42
- References
- 6
- FWCI
- 0.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of Neurotrophins in Multiple Sclerosis—Pathological and Clinical Implications. https://app.cochat.ai/papers/10.3390/ijms131013713
- The paper
- Kalinowska-Lyszczarz, A., & Losy, J. (2012). The Role of Neurotrophins in Multiple Sclerosis—Pathological and Clinical Implications. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms131013713
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.